Coronary Heart Disease
Conditions
Interventions
Experimental group:Berberine hydrochloride+Standard treatment
Control group:Standard treatment
Sponsors
First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged = 18 years old; 2. coronary angiography confirmed at least one coronary artery stenosis >70%; or left main lesion stenosis >50%; 3. Meet the diagnostic criteria for stable coronary heart disease; 4. There must be evidence of objective examination of myocardial ischemia: positive plate test, FFR <0.75, positive myocardial load test, etc.; 5. can not use the drugs prohibited in the program throughout the study; 6. A dose-loaded dual antiplatelet drug (ASA 300mg + clopidogrel 300mg) and any statin therapy have been given before PCI; 7. Subjects are willing to comply with all aspects of the research protocol, including adherence to the assigned treatment strategy, medication and follow-up; 8. To be able to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. combined with severe heart valve disease; 2. Consolidate severe congenital heart disease; 3. combined with hyperthyroidism such as hyperthyroidism and anemia; 4. combined with pulmonary heart disease; 5. combined with hypertrophic obstructive cardiomyopathy; 6. severe hypotension (SBP 160 mm Hg, and / or DBP > 100 mm Hg); 8. Hepatic insufficiency (defined as ALT or total bilirubin greater than 3 times the upper limit of normal); 9. renal insufficiency (defined as blood creatinine greater than 1.5 times the upper limit of normal); 10. Patients at high risk of bleeding, such as thrombocytopenia, blood system diseases, etc.; 11. Active peptic ulcer and skin ulcers; 12. Patients who are allergic to clopidogrel, aspirin, statins, and berberine; 13. Patients with a history of cardiogenic shock within two weeks; 14. Pregnant and lactating women, women of childbearing age who cannot be strictly contravented during treatment; 15. Participated in other clinical researchers in the past 3 months; 16. Those who do not have legal capacity or limited legal capacity; 17.. Any situation that the investigator believes is not suitable for participation in the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MACE; | — |
Secondary
| Measure | Time frame |
|---|---|
| all-cause death;cardiac death;ST;Nonfatal myocardial infarction;Target vessel reconstruction;Stroke;lipids change; | — |
Countries
China
Contacts
Public ContactXiang Xie
Heart Center, the First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed